The principal objective of the Biostatistics Core Facility is to provide statistical collaborative support of the highest quality to members of the Moffitt Cancer Center &Research Institute. Collaborative services include: assistance with design of studies, analytical aspects of grant applications, protocol development, sample size determination, and quantitative analysis and interpretation of data, usually resulting in peer-reviewed research articles. Core faculty are also involved in statistical methods development motivated by these research collaborations. The Facility, led by Dr. Michael Schell, has essentially tripled in size since the last review and now includes seven full-time faculty, five staff statisticians, and three part-time core members. The large growth in the size of Biostatistics since the last review translates to a corresponding breadth and depth of expertise. Substantial gains have occurred in the analysis of gene and tissue microarrays, proteomics, SNPs, group randomized trials, biomarkers, imaging studies, and structural equations modeling. Additional areas of strength include: clinical trials, gene microarray expression, SNP analysis, biomarker analysis, HPV incidence assessment and prevention, smoking cessation, and psychosocial issues in cancer. Recent methodological advances include development of the reduced piecewise exponential model for modeling survival, and a coordinated processing plan for the analysis of candidate biomarkers. Since the Moffitt Cancer Center is one of the leading centers for patient accruals among NCI-designated cancer centers, the Core is involved in a considerable volume of protocol activity. Faculty statisticians are members of two Scientific Review Committees, both of which meet monthly, and the Protocol Monitoring Committee. The Core requests CCSG Support of $428,029, which is 25% of its operational budget. The core continues to cost-effectively support all of the research programs.
; The Biostatistics Core is critical for the analytical quality of many research efforts at Moffitt. All institutional clinical trials are required to have statisticians, who are typically co-authors of phase II and III studies. Additionally, many studies involve high-dimensional data like gene microarrays, proteomics, SNP studies, and tissue microarrays that involve BCF members.
|Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612|
|Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53|
|Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303|
|Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73|
|Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :|
|Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880|
|Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029|
|Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :|
|Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :|
|Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96|
Showing the most recent 10 out of 974 publications